Immatics Reports 32% cORR in Phase 1 PRAME Melanoma Data
Immatics reported 32% cORR in PRAME-high melanoma from Phase 1b IMA402 data and 41% cORR across tumors in Phase 1 IMA203CD8 data. The company described safety as manageable and said next steps include combinations and targeted cohorts.